|
||||||
| Home |
| Find a Clinical Trial |
| Clinical Trial FAQs |
| About Informed Consent |
| Clinical Trials Glossary |
| Medical Research Areas |
| Clinical Trial Resources |
|
 |
Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only. | |
|
|
 |
|
|
|
|||
|
Novartis Clinical
Trials provides information about research studies recruiting
within the U.S. Visit ClinicalTrials.gov, a registry of federally and privately supported clinical trial for more information regarding clinical trials outside of the U.S. |
|
|
Find a Clinical Trial
Juvenile Arthritis
Juvenile arthritis (JA) is a term often used to describe arthritis in children. Children can develop almost all types of arthritis that affect adults, but the most common type that affects children is Juvenile Idiopathic Arthritis (JIA). JIA is a classification system for chronic arthritis in children. Pediatric rheumatologists throughout the world developed the JIA classification system, which includes more types of chronic arthritis that affect children. In general, the symptoms of JIA include joint pain, swelling, tenderness, warmth, and stiffness that last for more than 6 continuous weeks. [Source: www.niams.nih.gov]
Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial. For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy. Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.
Juvenile Idiopathic Arthritis (SJIA) Studies - G2301/G2305
Two studies are currently available for participation, the doctor will help you determine which study is right for you. The purpose of these two studies is to assess the initial and sustained efficacy and safety of a Novartis investigational drug in participants with SJIA having a flare. Both studies contain randomized, double-bind, placebo controlled parts but all subjects will receive the investigational drug at some point. An "investigational drug" is a drug that is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA)." An "investigational drug" is a drug that is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA).
Trial phase: Phase 3 Participation Duration: Depending on the trial, participant duration will range from 5 weeks with approximately 6 visits to at least 2 years with visits approximately every 4 weeks. Protocol Number: CACZ885G2301/CACZ885G2305 |